Thank you for reading this post, don't forget to subscribe!

Examine Evaluated the Efficacy, Security and Immunogenicity of ABP 959 In comparison with Eculizumab in Sufferers With Paroxysmal Nocturnal Hemoglobinuria

THOUSAND OAKS, Calif., Aug. 23, 2022 /PRNewswire/ — Amgen (NASDAQ: AMGN) at present introduced constructive top-line outcomes from the DAHLIA research, a randomized, double-blind, active-controlled, two-period crossover Section 3 research evaluating the efficacy and security of ABP 959, a biosimilar candidate to SOLIRIS® (eculizumab), in contrast with SOLIRIS in grownup sufferers with paroxysmal nocturnal hemoglobinuria (PNH).

The research met its main endpoints, demonstrating no clinically significant variations between ABP 959 and SOLIRIS based mostly on the management of intravascular hemolysis as measured by lactate dehydrogenase (LDH) at week 27 for the parallel comparability, and the time-adjusted space below the impact curve (AUEC) of LDH from week 13 to week 27, from week 39 to week 53, and from week 65 to week 79 for the crossover comparability. The security and immunogenicity profile of ABP 959 was akin to SOLIRIS.

“At present’s constructive outcomes with ABP 959 exhibit related efficacy, security and immunogenicity because the reference product, additional highlighting Amgen’s dedication to offering sufferers with entry to high-quality, biologic therapies,” mentioned David M. Reese, M.D., government vice chairman of Analysis and Growth at Amgen. “We sit up for working with regulators to make this potential biosimilar possibility out there to sufferers.”

Detailed outcomes of this research shall be offered at a future medical congress and submitted for publication.

ABP 959 is being developed as a biosimilar candidate to SOLIRIS, for the remedy of PNH and different indications. ABP 959 has the identical pharmaceutical type, dosage energy, route of administration and dosing routine as licensed eculizumab in the US (U.S.) and European Union (EU).

This isn’t a suggestion on the market. ABP 959 is at the moment not out there commercially.

Amgen has a complete of 11 biosimilars in its portfolio, together with 5 which have been permitted within the U.S., three which can be permitted within the EU, and three in Section 3 improvement.

In regards to the DAHLIA Examine

This Section 3 research is a randomized, double-blind, active-controlled, two-period crossover research in grownup sufferers with paroxysmal nocturnal hemoglobinuria (PNH), who’ve been beforehand handled with eculizumab for a minimum of six months. Topics have been randomized (1:1) to obtain every investigational product (IP) in 1 of two sequences, both remedy T adopted by remedy R (TR) or remedy R adopted by remedy T (RT). Therapy was administered over 2 durations: Interval 1 was 52 weeks in length; Interval 2 began at week 53 with a crossover in remedy and was 26 weeks in length.

Interval 1 (week 1 to week 53):   
Therapy T: ABP 959 at a dose of 900 mg intravenously (IV) each 14 ± 2 days for 52 weeks 
Therapy R: eculizumab at a dose of 900 mg IV each 14 ± 2 days for 52 weeks

Interval 2 (week 53 to week 79)   
Therapy T: ABP 959 at a dose of 900 mg IV each 14 ± 2 days for 26 weeks  
Therapy R: eculizumab at a dose of 900 mg IV each 14 ± 2 days for 26 weeks

About Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is a uncommon, life-threatening, bone marrow dysfunction characterised by intravascular hemolytic anemia, bone marrow failure, and thrombo-embolic episodes, and is related to a big enhance in mortality, improvement of arterial and venous thrombo-embolic episodes, visceral organ injury, and speedy deterioration in high quality of life.1,2,3,4 The illness is attributable to the growth of a clone of hematopoietic cells missing glycosylphosphatidylinositol-anchored membrane proteins, which ends up in power, complement-mediated intravascular hemolysis.2

About ABP 959

ABP 959 is an investigational biosimilar candidate to SOLIRIS® (eculizumab) for the remedy of paroxysmal nocturnal hemoglobinuria (PNH) and different indications. It’s a monoclonal antibody that particularly binds to the complement protein C5 and inhibits the development of each the classical and different complement cascades. ABP 959 has the identical amino acid sequence as eculizumab and equal non-clinical pharmacologic operate, based mostly on complete bioanalytical assays.

About Amgen Biosimilars

Amgen is dedicated to constructing upon Amgen’s expertise within the improvement and manufacturing of revolutionary human therapeutics to broaden Amgen’s attain to sufferers with severe sicknesses. Biosimilars assist to keep up Amgen’s dedication to attach sufferers with very important medicines, and Amgen is effectively positioned to leverage its almost 4 many years of expertise in biotechnology to create high-quality biosimilars and reliably provide them to sufferers worldwide.

For extra data, go to

About Amgen 

Amgen is dedicated to unlocking the potential of biology for sufferers affected by severe sicknesses by discovering, creating, manufacturing and delivering revolutionary human therapeutics. This method begins through the use of instruments like superior human genetics to unravel the complexities of illness and perceive the basics of human biology.  

Amgen focuses on areas of excessive unmet medical want and leverages its experience to attempt for options that enhance well being outcomes and dramatically enhance individuals’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one in every of the world’s main impartial biotechnology firms, has reached thousands and thousands of sufferers around the globe and is creating a pipeline of medicines with breakaway potential.  

Amgen is likely one of the 30 firms that comprise the Dow Jones Industrial Common and can also be a part of the Nasdaq-100 index.  In 2021, Amgen was named one of many 25 World’s Finest Workplaces™ by Fortune and Nice Place to Work™ and one of many 100 most sustainable firms on the planet by Barron’s.

For extra data, go to and comply with us on  

Amgen Ahead-Trying Statements

This information launch incorporates forward-looking statements which can be based mostly on the present expectations and beliefs of Amgen. All statements, aside from statements of historic truth, are statements that may very well be deemed forward-looking statements, together with any statements on the end result, advantages and synergies of collaborations, or potential collaborations, with some other firm (together with BeiGene, Ltd., Kyowa-Kirin Co., Ltd., or any collaboration to fabricate therapeutic antibodies in opposition to COVID-19), the efficiency of Otezla® (apremilast) (together with anticipated Otezla gross sales progress and the timing of non-GAAP EPS accretion), the 5 Prime Therapeutics, Inc. acquisition, or the Teneobio, Inc. acquisition or the not too long ago introduced proposed acquisition of ChemoCentryx, Inc., in addition to estimates of revenues, working margins, capital expenditures, money, different monetary metrics, anticipated authorized, arbitration, political, regulatory or scientific outcomes or practices, buyer and prescriber patterns or practices, reimbursement actions and outcomes, results of pandemics or different widespread well being issues comparable to the continuing COVID-19 pandemic on our enterprise, and different such estimates and outcomes. Ahead-looking statements contain important dangers and uncertainties, together with these mentioned beneath and extra totally described within the Securities and Change Fee studies filed by Amgen, together with our most up-to-date annual report on Kind 10-Ok and any subsequent periodic studies on Kind 10-Q and present studies on Kind 8-Ok. Except in any other case famous, Amgen is offering this data as of the date of this information launch and doesn’t undertake any obligation to replace any forward-looking statements contained on this doc because of new data, future occasions or in any other case.

No forward-looking assertion will be assured and precise outcomes might differ materially from these we mission. Discovery or identification of recent product candidates or improvement of recent indications for current merchandise can’t be assured and motion from idea to product is unsure; consequently, there will be no assure that any explicit product candidate or improvement of a brand new indication for an current product shall be profitable and turn out to be a business product. Additional, preclinical outcomes don’t assure protected and efficient efficiency of product candidates in people. The complexity of the human physique can’t be completely, or generally, even adequately modeled by pc or cell tradition techniques or animal fashions. The size of time that it takes for us to finish scientific trials and acquire regulatory approval for product advertising has up to now assorted and we anticipate related variability sooner or later. Even when scientific trials are profitable, regulatory authorities might query the sufficiency for approval of the trial endpoints we have now chosen. We develop product candidates internally and thru licensing collaborations, partnerships and joint ventures. Product candidates which can be derived from relationships could also be topic to disputes between the events or might show to be not as efficient or as protected as we might have believed on the time of getting into into such relationship. Additionally, we or others may establish security, unintended effects or manufacturing issues with our merchandise, together with our gadgets, after they’re available on the market.

Our outcomes could also be affected by our skill to efficiently market each new and current merchandise domestically and internationally, scientific and regulatory developments involving present and future merchandise, gross sales progress of not too long ago launched merchandise, competitors from different merchandise together with biosimilars, difficulties or delays in manufacturing our merchandise and international financial circumstances. As well as, gross sales of our merchandise are affected by pricing strain, political and public scrutiny and reimbursement insurance policies imposed by third-party payers, together with governments, non-public insurance policy and managed care suppliers and could also be affected by regulatory, scientific and guideline developments and home and worldwide developments towards managed care and healthcare price containment. Moreover, our analysis, testing, pricing, advertising and different operations are topic to in depth regulation by home and overseas authorities regulatory authorities. Our enterprise could also be impacted by authorities investigations, litigation and product legal responsibility claims. As well as, our enterprise could also be impacted by the adoption of recent tax laws or publicity to extra tax liabilities. If we fail to satisfy the compliance obligations within the company integrity settlement between us and the U.S. authorities, we may turn out to be topic to important sanctions. Additional, whereas we routinely acquire patents for our merchandise and know-how, the safety provided by our patents and patent functions could also be challenged, invalidated or circumvented by our rivals, or we might fail to prevail in current and future mental property litigation. We carry out a considerable quantity of our business manufacturing actions at a number of key amenities, together with in Puerto Rico, and likewise rely upon third events for a portion of our manufacturing actions, and limits on provide might constrain gross sales of sure of our present merchandise and product candidate improvement. An outbreak of illness or related public well being menace, comparable to COVID-19, and the general public and governmental effort to mitigate in opposition to the unfold of such illness, may have a big opposed impact on the availability of supplies for our manufacturing actions, the distribution of our merchandise, the commercialization of our product candidates, and our scientific trial operations, and any such occasions might have a cloth opposed impact on our product improvement, product gross sales, enterprise and outcomes of operations. We depend on collaborations with third events for the event of a few of our product candidates and for the commercialization and gross sales of a few of our business merchandise. As well as, we compete with different firms with respect to a lot of our marketed merchandise in addition to for the invention and improvement of recent merchandise. Additional, some uncooked supplies, medical gadgets and element elements for our merchandise are equipped by sole third-party suppliers. Sure of our distributors, clients and payers have substantial buying leverage of their dealings with us. The invention of great issues with a product just like one in every of our merchandise that implicate a whole class of merchandise may have a cloth opposed impact on gross sales of the affected merchandise and on our enterprise and outcomes of operations. Our efforts to collaborate with or purchase different firms, merchandise or know-how, and to combine the operations of firms or to help the merchandise or know-how we have now acquired, is probably not profitable. A breakdown, cyberattack or data safety breach may compromise the confidentiality, integrity and availability of our techniques and our knowledge. Our inventory value is risky and could also be affected by a variety of occasions. Our enterprise and operations could also be negatively affected by the failure, or perceived failure, of attaining our environmental, social and governance goals. The results of worldwide local weather change and associated pure disasters may negatively have an effect on our enterprise and operations. World financial circumstances might enlarge sure dangers that have an effect on our enterprise. Our enterprise efficiency may have an effect on or restrict the power of our Board of Administrators to declare a dividend or our skill to pay a dividend or repurchase our widespread inventory. We might not have the ability to entry the capital and credit score markets on phrases which can be favorable to us, or in any respect.

The scientific data mentioned on this information launch associated to our product candidates is preliminary and investigative. Such product candidates are usually not permitted by the U.S. Meals and Drug Administration, and no conclusions can or must be drawn relating to the security or effectiveness of the product candidates. Additional, any scientific data mentioned on this information launch regarding new indications for our merchandise is preliminary and investigative and isn’t a part of the labeling permitted by the U.S. Meals and Drug Administration for the merchandise. The merchandise are usually not permitted for the investigational use(s) mentioned on this information launch, and no conclusions can or must be drawn relating to the security or effectiveness of the merchandise for these makes use of.

CONTACT: Amgen, Thousand Oaks   
Kelley Davenport, 202-585-9637 (media)  
Megan Fox, 805-447-1423 (media)  
Arvind Sood, 805-447-1060 (traders) 

1 Kelly R, Richards S, Hillmen P, Hill A. The pathophysiology of paroxysmal nocturnal hemoglobinuria and remedy with eculizumab. Ther Clin Threat Manag. 2009;5:911-921.  
2 Hill A, Richards SJ, Hillmen P. Current developments within the understanding and administration of paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2007;137:181-192.  
3 Hillmen P, Younger NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-1243.  
4 Rother RP, Bell L, Hillmen P, et al. The scientific sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human illness. JAMA. 2005;293:1653-1662.


Supply hyperlink